Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial.

Clin Cancer Res · 2022 · PMC9365376 · PMID 35275991

Europe PMC DOI

hedged sentences

0.1506

closest p · 3.0× alpha

0.1506

boldest claim

The sentences

a nonsignificant trendP = 0.1506not close (p > 0.1)

A nonsignificant trend for the biomarker effect was also observed in both treatment groups in the adjusted analyses (alectinib HR = 1.95; 95% CI, 0.78–4.83; P = 0.1506; and crizotinib HR = 1.52; 95% CI, 0.88–2.63; P = 0.1323).

also in 5,406 other papers

a slight trendno p-value reported

We also noted a slight trend for higher cfDNA concentrations in patients with CNS lesions, which may be a further indicator of higher overall tumor burden.

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.